Traduction de «from the application » (Néerlandais → Français) :

Encouraging clinical trials and the inherent evaluation of applications for these trials, as well as the creation of a scientific subgroup for oncology, means that the FAMHP will need to have the necessary autonomy to attract the essential expertise for this relatively complex domain from the point of concept of innovative medicines.
Encouraging clinical trials and the inherent evaluation of applications for these trials, as well as the creation of a scientific subgroup for oncology, means that the FAMHP will need to have the necessary autonomy to attract the essential expertise for this relatively complex domain from the point of concept of innovative medicines.

Data input happens manually. Information about the bookings, such as the reconciliation of fees and the corresponding service applications, is mainly obtained from the MeSeA system, more specifically through verification of the “public inbox payment tracking”.
Data input happens manually. Information about the bookings, such as the reconciliation of fees and the corresponding service applications, is mainly obtained from the MeSeA system, more specifically through verification of the “public inbox payment tracking”.

The Clinical Trial Facilitation Group (CTFG) is a collaborative effort to facilitate and harmonise clinical trials in Europe. Within the CTFG agreements have been made for various competent authorities to voluntarily arrive at a common evaluation for applications for clinical trials whenever this involves multicentre trials with participating centres from different Member States.
The Clinical Trial Facilitation Group (CTFG) is a collaborative effort to facilitate and harmonise clinical trials in Europe. Within the CTFG agreements have been made for various competent authorities to voluntarily arrive at a common evaluation for applications for clinical trials whenever this involves multicentre trials with participating centres from different Member States.

The law of 7 May 2004 relating to experiments on the human person in Belgium provides that any objections from the FAMHP need to be submitted within a maximum of 28 days following the validation of applications for clinical trials.
The law of 7 May 2004 relating to experiments on the human person in Belgium provides that any objections from the FAMHP need to be submitted within a maximum of 28 days following the validation of applications for clinical trials.

European procedures in which Belgium was acting as RMS or (co)-rapporteur ●● The switch from paper documents to electronic applications
European procedures in which Belgium was acting as RMS or (co)-rapporteur ●● The switch from paper documents to electronic applications

The medicine market itself determines the rate of inspections resulting from authorisation applications and variations.
The medicine market itself determines the rate of inspections resulting from authorisation applications and variations.

- Application of Rasival withdrawn from EMA
- Demande pour Rasival retirée de

The US FDA has extended its review of the supplemental New Drug Application for Zometa in the adjuvant (postsurgery) treatment of premenopausal women with early breast cancer in conjunction with hormonal therapy from the fourth quarter of 2010 to the first quarter of 2011.
Aux Etats-Unis, la FDA a prolongé du quatrième trimestre 2010 au premier trimestre 2011 son examen d’une autorisation supplémentaire de mise sur le marché (New Drug Application NDA) pour Zometa en conjonction avec un traitement hormonal chez les femmes préménopausées atteinte d’un cancer du sein à un stade précoce.

In a report of 15 January 2009, the European Food Safety Authority (EFSA) gives its opinion about the innocuousness of taurine and D-glucuronolactone as individual ingredients of energy drinks. This is based on new data from the literature and recent studies by the same applicant (EFSA, 2009).
Enfin, dans un rapport du 15 janvier 2009, l’European Food Safety Authority (EFSA) se prononce sur l’innocuité de la taurine et de la D-glucuronolactone en tant qu’ingrédients individuels de boissons énergisantes en se fondant sur les données récentes de la littérature et de nouvelles études fournies par le même pétitionnaire mais ne procède pas à une évaluation de l’innocuité de ces boissons en tant que telles (EFSA, 2009).

Import-Export licence The graph below shows the upward trend since 2002, with the number of applications increasing from 350 to 400 per year.
Import-Export licence The graph below shows the upward trend since 2002, with the number of applications increasing from 350 to 400 per year.